Novo Nordisk's insulin aspart franchise is a DKK 10.6 billion ($1.5 billion) business worldwide, with NovoLog (known as NovoRapid outside the US) making up the bulk (around DKK 9 billion ...
That suggests its top-selling insulin products like rapid-acting NovoRapid (insulin aspart), premix NovoMix (insulin aspart/insulin aspart protamine) and long-acting Tresiba (insulin degludec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback